Explore All 295 IPO Life Science Deals - Search the Database Free
Investment Summary |
|
|---|---|
| Date | June 18, 2021 |
| Target | Ambrx |
| Sector | Life Science |
| Sellers(s) |
HBM Partners
DCP Capital WuXi AppTec Fosun Pharma |
| Deal Type | IPO |
FILTER BY
| Category | Private Equity Firm |
|---|---|
| Founded | 2001 |
| PE ASSETS | 2.1B USD |
| Size | Large |
| Type | Sector Focused |
HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.
| Deal Context for Seller | # |
|---|---|
| Overall | 26 of 40 |
| Sector: Life Science | 24 of 35 |
| Type: IPO | 22 of 30 |
| State: California | 6 of 9 |
| Country: United States | 19 of 27 |
| Year: 2021 | 8 of 11 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-06-10 |
Tata 1mg
New Delhi, India Tata 1mg is an online pharmacy network and medicine search engine that allows users to order medicines and book for diagnostic test. Tata 1mg was founded in 2012 and is based in New Delhi, New Delhi. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-06-23 |
Monte Rosa Therapeutics
Boston, Massachusetts, United States Monte Rosa Therapeutics is a biotechnology company developing molecular glues to degrade disease-causing proteins. The company has developed a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection, and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa Therapeutics was founded in 2018 and is based in Boston, Massachusetts. |
Sell | - |
DCP is a private equity firm focused on long-term partnerships with management teams in companies across Asia. The Firm seeks businesses with growth potential in a variety of industries including business services, consumer products, distribution, food, manufacturing, financial services, real estate, and staffing. DCP is headquartered in Beijing, China.
| Deal Context for Seller | # |
|---|---|
| Overall | 2 of 4 |
| Sector: Life Science | 1 of 1 |
| Type: IPO | 2 of 3 |
| State: California | 1 of 1 |
| Country: United States | 1 of 1 |
| Year: 2021 | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-05-07 |
Dejin Medical
Hangzhou, China Dejin Medical is focusing on the research and development of related treatment technologies for mitral and tricuspid valves. Dejin Medical was founded in 2015 and is based in Hangzhou, China. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-06-21 |
51job
Shanghai, China 51job is a provider of integrated human resource services in China. With a comprehensive suite of HR solutions, 51job meets the needs of enterprises and job seekers through the entire talent management cycle, from initial recruitment to employee retention and career development. 51job was founded in 1998 and is based in Shanghai, China. |
Buy | $5.7B |
| Category | Company |
|---|---|
| Founded | 2000 |
| Sector | Life Science |
| Employees | 37,832 |
| Revenue | 39.2B CNY (2024) |
WuXi AppTec is a provider of pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi AppTec was founded in 2000 and is based in Shanghai, China.
| Deal Context for Seller | # |
|---|---|
| Overall | 1 of 4 |
| Sector: Life Science | 1 of 4 |
| Type: IPO | 1 of 2 |
| State: California | 1 of 1 |
| Country: United States | 1 of 2 |
| Year: 2021 | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-03-02 |
OXGENE
Oxford, United Kingdom OXGENE provides end-to-end contractual services to cell and gene therapy companies seeking to discover, develop, manufacture and test innovative drugs at scale for global commercialization. OXGENE provides rapid and cost-effective services using proprietary technologies and automation platforms for molecular discovery and integrating the full range of technologies required to manufacture cell and gene therapies. OXGENE was founded in 2011 and is based in Oxford, United Kingdom. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-12-10 |
CANbridge
Suzhou, China CANbridge is a biotechnology company focused on developing and commercializing rare disease therapeutics in China. CANbridge was founded in 2012 and is based in Suzhou, China. |
Sell | - |
| Category | Company |
|---|---|
| Founded | 1994 |
| Sector | Healthcare Services |
| Employees | 40,234 |
| Revenue | 41.1B CNY (2024) |
Fosun Pharma is a healthcare company in China that strategically covers important segments of the healthcare industry value chain, including pharmaceutical manufacturing, pharmaceutical distribution and retail, healthcare services, diagnostic products, and medical devices. Fosun Pharma was founded in 1994 and is based in Shanghai, China.
| Deal Context for Seller | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science | 1 of 1 |
| Type: IPO | 1 of 1 |
| State: California | 1 of 1 |
| Country: United States | 1 of 1 |
| Year: 2021 | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-12-14 |
Tridem Pharma
Escalquens, France Tridem Pharma is specialized in the distribution of drugs, medical promotion and regulatory affairs in the French-speaking African countries and territories. Tridem Pharma was founded in 1986 and is based in Escalquens, France. |
Buy | - |
